GlassScriptPhysician profile
Andalib Danandeh
NPI 1093200123
$3,894.80
in general payments reported to CMS, 2019-2025
30 companies · $288 in 2025
The $288 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.55 · 2021: $16.35 · 2022: $478 · 2023: $1,649 · 2024: $1,450 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,387.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $713.16 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $402.42 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $373.97 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $341.55 | 2022-2025 | |
| Abbvie INC. | $297.96 | 2022-2024 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $284.85 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Otsuka America Pharmaceutical, INC. | $180.92 | 2022-2024 | Rexulti |
| Myriad Women'S Health, INC. | $178.26 | 2023 | Myrisk |
| Amgen INC. | $157.12 | 2019-2024 | Prolia, Evenity, Otezla |
| Boston Scientific Corporation | $156.22 | 2023-2024 | Wavewriter Alpha Prime 16 |
| Exact Sciences Corporation | $96.52 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.53 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $80.07 | 2022-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Sumitomo Pharma America, INC. | $76.17 | 2024 | Gemtesa |
| Inspire Medical Systems, INC. | $60.80 | 2024-2025 | Inspire |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $45.32 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $42.82 | 2022-2023 | |
| Astellas Pharma US INC | $42.81 | 2023-2025 | Veozah |
| Medtronic, INC. | $36.94 | 2022 | |
| Nevro Corp. | $34.12 | 2023 | Senza |
| Insulet Corporation | $32.93 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.61 | 2022 | |
| Phathom Pharmaceuticals, INC. | $23.04 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $20.23 | 2022 | |
| Dexcom, INC. | $19.43 | 2024 | Dexcom G6 Transmitter |
| Eisai INC. | $16.71 | 2024 | |
| Xeris Pharmaceuticals, INC. | $16.58 | 2025 | Gvoke Hypopen |
| Antares Pharma, INC. | $16.52 | 2024 | Xyosted |
| Vbi Vaccine (Delaware) INC. | $16.36 | 2022 | |
| Pharmacosmos Therapeutics INC. | $12.86 | 2023 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andalib Danandeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.